| Literature DB >> 34044584 |
Julie N Graff1,2, Li Wen Liang3, Jeri Kim4, Arnulf Stenzl5.
Abstract
Current treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) are noncurative, and median survival upon development of mCRPC is approximately 3 years. The novel hormonal agent enzalutamide has an established role in the mCRPC treatment paradigm, and emerging evidence suggests potential synergism with enzalutamide and the PD-1 inhibitor pembrolizumab in men with mCRPC. Here, we describe the design and rationale for the multicenter, randomized, double-blind, Phase III KEYNOTE-641 study, which will be conducted to compare the efficacy and safety of pembrolizumab plus enzalutamide with that of enzalutamide plus placebo in mCRPC. Clinical trial registration: NCT03834493 (ClinicalTrials.gov).Entities:
Keywords: PD-1; PD-L1; castration resistant; enzalutamide; mCRPC; pembrolizumab; prostate cancer
Mesh：
Substances：
Year: 2021 PMID： 34044584 DOI： 10.2217/fon-2020-1008
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404